A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib; Doxorubicin liposomal; Filgrastim
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 20 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
- 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.